Implication for health policy/practice/research/medical education:
A review of recent retrospective cohort studies found that nirmatrelvir-ritonavir (Paxlovid) has a big impact on lowering the chances of hospitalization, severe disease progression, and death in high-risk COVID-19 patients, even those who had immunity before. To confirm these results and evaluate Paxlovid’s long-term effectiveness and safety in a variety of patient population demographics, more studies must be conducted.
Please cite this paper as: Amin A, Maleki S, Moonesan MR. Nirmatrelvir-ritonavir efficacy and safety in high-risk COVID-19 patients: a review of recent retrospective cohort studies – nephrology point of view. J Renal Inj Prev. 2024; x(x): e32257. doi: 10.34172/jrip.2024.32257.